Publications
Selected publications
Barisic D, Chin CR, Meydan C, Teater M, Tsialta I, Mlynarczyk C, Chadburn A, Wang X, Sarkozy M, Xia M, Carson SE, Raggiri S, Debek S, Pelzer B, Durmaz C, Deng Q, Lakra P, Rivas M, Steidl C, Scott DW, Weng AP, Mason CE, Green MR, Melnick A. ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis. Cancer Cell. 2024 Apr 8;42(4):720-722. doi: 10.1016/j.ccell.2024.03.012. PubMed PMID: 38593783.
Venturutti L, Rivas MA, Pelzer BW, Flümann R, Hansen J, Karagiannidis I, Xia M, McNally DR, Isshiki Y, Lytle A, Teater M, Chin CR, Meydan C, Knittel G, Ricker E, Mason CE, Ye X, Pan-Hammarström Q, Steidl C, Scott DW, Reinhardt HC, Pernis AB, Béguelin W, Melnick AM. An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas. Cancer Discov. 2023 Jan 9;13(1):216-243. doi: 10.1158/2159-8290.CD-22-0561. PubMed PMID: 36264161; PubMed Central PMCID: PMC9839622.
Rivas MA, Meydan C, Chin CR, Challman MF, Kim D, Bhinder B, Kloetgen A, Viny AD, Teater MR, McNally DR, Doane AS, Béguelin W, Fernández MTC, Shen H, Wang X, Levine RL, Chen Z, Tsirigos A, Elemento O, Mason CE, Melnick AM. Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation. Nat Immunol. 2021 Feb;22(2):240-253. doi: 10.1038/s41590-020-00827-8. Epub 2021 Jan 11. PMID: 33432228
Rivas MA, Durmaz C, Kloetgen A, Chin CR, Chen Z, Bhinder B, Koren A, Viny AD, Scharer CD, Boss JM, Elemento O, Mason CE, Melnick AM.Cohesin Core Complex Gene Dosage Contributes to Germinal Center Derived Lymphoma Phenotypes and Outcomes. Front Immunol. 2021 Sep 21;12:688493. doi: 10.3389/fimmu.2021.688493. eCollection 2021. PMID: 34621263
Doane AS, Chu CS, Di Giammartino D, Rivas MA, Hellmuth JC, Yusufova N, Alonso A, Apostolou E, Roeder R, Elemento O, Jiang Y, Melnick AM. OCT2 pre-positioning facilitates cell fate transition and chromatin architecture changes in humoral immunity. Nat Immunol. 2021 Oct;22(10):1327-1340. doi: 10.1038/s41590-021-01025-w. Epub 2021 Sep 23. PMID: 34556886
Béguelin W, Teater M, Meydan C, Hoehn KB, Phillip JM, Soshnev AA, Venturutti L, Rivas MA, Calvo-Fernández MT, Gutierrez J, Camarillo JM, Takata K, Tarte K, Kelleher NL, Steidl C, Mason CE, Elemento O, Allis CD, Kleinstein SH, Melnick AM. Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response. Cancer Cell. 2020 May 11;37(5):655-673.e11. doi: 10.1016/j.ccell.2020.04.004. PMID: 32396861
Rivas MA, Melnick AM. Role of chromosomal architecture in germinal center B cells and lymphomagenesis. Curr Opin Hematol. 2019 Apr 24;. doi: 10.1097/MOH.0000000000000505. [Epub ahead of print] PubMed PMID: 31033702.
Béguelin W, Rivas MA, Calvo Fernández MT, Teater M, Purwada A, Redmond D, Shen H, Challman MF, Elemento O, Singh A, Melnick AM. EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop. Nat Commun. 2017 Oct 12;8(1):877. doi: 10.1038/s41467-017-01029-x. PubMed PMID: 29026085; PubMed Central PMCID: PMC5638898.
Viny AD, Ott CJ, Spitzer B, Rivas M, Meydan C, Papalexi E, Yelin D, Shank K, Reyes J, Chiu A, Romin Y, Boyko V, Thota S, Maciejewski JP, Melnick A, Bradner JE, Levine RL. Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis. J Exp Med. 2015 Oct 19;212(11):1819-32. doi: 10.1084/jem.20151317. Epub 2015 Oct 5. PubMed PMID: 26438361; PubMed Central PMCID: PMC4612085.
García-García C,* Rivas MA,* Ibrahim YH, Calvo MT, Gris-Oliver A, Rodríguez O, Grueso J, Antón P, Guzmán M, Aura C, Nuciforo P, Jessen K, Argilés G, Dienstmann R, Bertotti A, Trusolino L, Matito J, Vivancos A, Chicote I, Palmer HG, Tabernero J, Scaltriti M, Baselga J, Serra V. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. Clin Cancer Res. 2015 Dec 15;21(24):5499-5510. doi: 10.1158/1078-0432.CCR-14-3091. Epub 2015 Aug 13. PubMed PMID: 26272063; PubMed Central PMCID: PMC5087596. *Shared first authorship.
Rivas MA, Venturutti L, Huang YW, Schillaci R, Huang TH, Elizalde PV. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development. Breast Cancer Res. 2012 May 14;14(3):R77. doi: 10.1186/bcr3187. PubMed PMID: 22583478; PubMed Central PMCID: PMC3446340.
Rivas MA, Tkach M, Beguelin W, Proietti CJ, Rosemblit C, Charreau EH, Elizalde PV, Schillaci R. Transactivation of ErbB-2 induced by tumor necrosis factor alpha promotes NF-kappaB activation and breast cancer cell proliferation. Breast Cancer Res Treat. 2010 Jul;122(1):111-24. doi: 10.1007/s10549-009-0546-3. Epub 2009 Sep 18. PubMed PMID: 19760502.
Rivas MA, Carnevale RP, Proietti CJ, Rosemblit C, Beguelin W, Salatino M, Charreau EH, Frahm I, Sapia S, Brouckaert P, Elizalde PV, Schillaci R. TNF alpha acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways. Exp Cell Res. 2008 Feb 1;314(3):509-29. doi: 10.1016/j.yexcr.2007.10.005. Epub 2007 Oct 13. PubMed PMID: 18061162.
Full list of publications can be found in Pubmed, Google Scholar or ORCID.